EU-funded projects

Our ongoing projects 

ASCERTAIN 

EHA is a partner in the ASCERTAIN project. ASCERTAIN stands for Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies.  

The project is the result of years advocacy and multistakeholder discussions and is founded by the EU’s Horizon Europe program.​ It seeks to promote: 

  • access to affordable technologies 
  • the need to stimulate innovation and entrepreneurship, and  
  • the need to consider the environmental impact of innovations.

ASCERTAIN will develop open-access, easy to use, policy-supporting tools including pricing models and value assessment models. These should:  

  • Improve transparency and accountability of decision-making,  
  • Reduce uncertainty for all stakeholders,  
  • Reward innovation in areas of high unmet need,  
  • Accelerate access for patients, and  
  • Support long-term planning in a sustainable way.

In ASCERTAIN, EHA collaborates with patients, payers, regulators, manufacturers and health economists. The projects ends in November 2026. 

EU funding calls 

Horizon Europe 

EU4Health

No calls at the moment.  

Previous projects 

SUPPLY 

Due to the importance of plasma for hematology, EHA joined the SUPPLY (Strengthening voluntary non-remunerated plasma collection capacity in Europe) project.   

This consortium, which received funding from the EU4Health program and was coordinated by the European Blood Alliance, was made up of 20 diverse stakeholders. From September 2022 to February 2024, they worked together to evaluate legal frameworks and policies on plasma collection in Europe.   

EHA led the SUPPLY work package on:   

  • Developing recommendations on the clinical use of immunoglobulins   
  • The prioritization of such use in times of crisis  

The final recommendations, with input from EHA experts Cynthia So-Osman (transfusion medicine) and Isabelle Durand-Zaleski (public health and health economics), can be found in the report on SUPPLY work package 6.  

All the reports resulting from the project are available on the SUPPLY resources webpage.   

HARMONY 

EHA was a partner in the HARMONY and HARMONY PLUS projects, funded by the Innovative Medicines Initiative (IMI, now IHI), from 2017 through 2024. 

HARMONY leveraged big data to help improve the care of patients with blood cancers. It gathered, integrated and analyzed anonymous patient data to define clinical endpoints and outcomes that are recognized by all key stakeholders. 

The project’s data sharing platform aimed to facilitate research as well as decision making by both policy makers and clinicians. 

GAPP Joint Action 

We were a collaborating stakeholder in the GAPP Joint Action, which ran from 2018 to 2021.

GAPP main objectives were: 

  • Increasing consistency and efficacy of competent authority regulatory activities through harmonization of EU-level tools for authorization procedures for preparation processes at blood and tissues establishments 
  • Developing a concept model for a European knowledge-sharing platform to support competent authorities in the assessment and evaluation of novel preparation processes of products 
  • Developing an international network of (trained) experts to support competent authorities in these tasks 

PROFILE 

EHA was a partner in the PROFILE project, funded through the EU’s Horizon 2020 program. The project ran from 2016 to 2021. 

PROFILE was an innovative training network which sought to rectify the shortcomings of current novel diagnostics and therapeutics for autoimmune diseases. Its focus was TTP (thrombotic thrombocytopenic purpura), a rare blood disorder.  

The academic and corporate partners in PROFILE also provided a joint European Industrial doctoral training program. This allowed PhD students to develop skills, both inside and outside of academia, that respond to public and private sector needs.  

EUnetHTA and EUnetHTA 21 

 EHA supported the work of the EUnetHTA consortium. This project piloted collaboration between EU Member States on Health Technology Assessment (HTA), by identifying and facilitating the involvement of leading experts in hematology in joint clinical assessments.  

Our support to EUnetHTA is an example of how we ensure that the expert views of hematologists are considered in all relevant EU decision-making and regulatory processes.  

EHA also provided input to the EUnetHTA 21 consortium which was commissioned with developing methodologies, guidance and a stakeholder framework for the implementation of the HTAR. 

Share